Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
October 27, 2022 09:00 ET
|
Assertio Holdings, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
Assertio to Participate in October 2022 Investor Conferences
October 12, 2022 07:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio to Participate in the 2022 Lake Street BIG6 Conference
September 07, 2022 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Closing of $70 Million Convertible Senior Notes Offering
August 25, 2022 10:24 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Prices $60 Million Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
August 22, 2022 22:06 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Proposed Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
August 22, 2022 16:01 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Second Quarter 2022 Financial Results
August 08, 2022 07:00 ET
|
Assertio Holdings, Inc.
Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance LAKE FOREST, Ill., Aug. 08, 2022 ...
Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
July 25, 2022 08:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...